APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Vaccines for Infectious Diseases

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global mRNA Vaccines for Infectious Diseases Market Outlook and Growth Opportunities 2026

19 December 2025195 pages

Choose your research edition.

Industry ResearchmRNA Vaccines for Infectious Diseases Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Vaccines for Infectious Diseases Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal mRNA Vaccines for Infectious Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Vaccines for Infectious Diseases Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Vaccines for Infectious Diseases Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global mRNA Vaccines for Infectious Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the mRNA Vaccines for Infectious Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the mRNA Vaccines for Infectious Diseases market include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global mRNA Vaccines for Infectious Diseases market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA Vaccines for Infectious Diseases and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Vaccines for Infectious Diseases revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global mRNA Vaccines for Infectious Diseases market.

mRNA Vaccines for Infectious Diseases Segment by Company

Translate Bio

Tiba Biotechnology

Sangamo Therapeutics

Moderna Therapeutics

In-Cell-Art

Ethris

eTheRNA

CureVac

BioNTech

Argos Therapeutics

mRNA Vaccines for Infectious Diseases Segment by Type

Infectious Disease Vaccines

Cancer Vaccines

mRNA Vaccines for Infectious Diseases Segment by Application

Infectious Disease

Cancer

mRNA Vaccines for Infectious Diseases Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global mRNA Vaccines for Infectious Diseases status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the mRNA Vaccines for Infectious Diseases key companies, revenue, market share, and recent developments.

3. To split the mRNA Vaccines for Infectious Diseases breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions mRNA Vaccines for Infectious Diseases market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Vaccines for Infectious Diseases significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Vaccines for Infectious Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines for Infectious Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines for Infectious Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines for Infectious Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccines for Infectious Diseases industry.

Chapter 3: Detailed analysis of mRNA Vaccines for Infectious Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of mRNA Vaccines for Infectious Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of mRNA Vaccines for Infectious Diseases in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Vaccines for Infectious Diseases Industry Trends Table 2. mRNA Vaccines for Infectious Diseases Industry Drivers Table 3. mRNA Vaccines for Infectious Diseases Industry Opportunities and Challenges Table 4. mRNA Vaccines for Infectious Diseases Industry Restraints Table 5. Global mRNA Vaccines for Infectious Diseases Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Vaccines for Infectious Diseases Revenue Share by Company (2021-2026) Table 7. Global mRNA Vaccines for Infectious Diseases Company Ranking, (2024-2026) & (US$ Million) Table 8. Global mRNA Vaccines for Infectious Diseases Key Company Manufacturing Base & Headquarters Table 9. Global mRNA Vaccines for Infectious Diseases Company, Product Type & Application Table 10. Global mRNA Vaccines for Infectious Diseases Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global mRNA Vaccines for Infectious Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Infectious Disease Vaccines Table 15. Significant Companies of Cancer Vaccines Table 16. Global mRNA Vaccines for Infectious Diseases Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global mRNA Vaccines for Infectious Diseases Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global mRNA Vaccines for Infectious Diseases Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Type (2021-2026) Table 20. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Infectious Disease Table 22. Significant Companies of Cancer Table 23. Global mRNA Vaccines for Infectious Diseases Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global mRNA Vaccines for Infectious Diseases Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global mRNA Vaccines for Infectious Diseases Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Application (2021-2026) Table 27. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Application (2027-2032) Table 28. Global mRNA Vaccines for Infectious Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global mRNA Vaccines for Infectious Diseases Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Region (2021-2026) Table 31. Global mRNA Vaccines for Infectious Diseases Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Region (2027-2032) Table 33. Global mRNA Vaccines for Infectious Diseases Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global mRNA Vaccines for Infectious Diseases Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global mRNA Vaccines for Infectious Diseases Sales Value Market Share by Country (2021-2026) Table 36. Global mRNA Vaccines for Infectious Diseases Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global mRNA Vaccines for Infectious Diseases Sales Value Market Share by Country (2027-2032) Table 38. Translate Bio Company Information Table 39. Translate Bio Business Overview Table 40. Translate Bio mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Translate Bio mRNA Vaccines for Infectious Diseases Product Portfolio Table 42. Translate Bio Recent Development Table 43. Tiba Biotechnology Company Information Table 44. Tiba Biotechnology Business Overview Table 45. Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product Portfolio Table 47. Tiba Biotechnology Recent Development Table 48. Sangamo Therapeutics Company Information Table 49. Sangamo Therapeutics Business Overview Table 50. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio Table 52. Sangamo Therapeutics Recent Development Table 53. Moderna Therapeutics Company Information Table 54. Moderna Therapeutics Business Overview Table 55. Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio Table 57. Moderna Therapeutics Recent Development Table 58. In-Cell-Art Company Information Table 59. In-Cell-Art Business Overview Table 60. In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. In-Cell-Art mRNA Vaccines for Infectious Diseases Product Portfolio Table 62. In-Cell-Art Recent Development Table 63. Ethris Company Information Table 64. Ethris Business Overview Table 65. Ethris mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Ethris mRNA Vaccines for Infectious Diseases Product Portfolio Table 67. Ethris Recent Development Table 68. eTheRNA Company Information Table 69. eTheRNA Business Overview Table 70. eTheRNA mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. eTheRNA mRNA Vaccines for Infectious Diseases Product Portfolio Table 72. eTheRNA Recent Development Table 73. CureVac Company Information Table 74. CureVac Business Overview Table 75. CureVac mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. CureVac mRNA Vaccines for Infectious Diseases Product Portfolio Table 77. CureVac Recent Development Table 78. BioNTech Company Information Table 79. BioNTech Business Overview Table 80. BioNTech mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. BioNTech mRNA Vaccines for Infectious Diseases Product Portfolio Table 82. BioNTech Recent Development Table 83. Argos Therapeutics Company Information Table 84. Argos Therapeutics Business Overview Table 85. Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Argos Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio Table 87. Argos Therapeutics Recent Development Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. mRNA Vaccines for Infectious Diseases Product Image Figure 2. Global mRNA Vaccines for Infectious Diseases Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Vaccines for Infectious Diseases Market Size (2021-2032) & (US$ Million) Figure 4. Global mRNA Vaccines for Infectious Diseases Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Infectious Disease Vaccines Image Figure 8. Cancer Vaccines Image Figure 9. Global mRNA Vaccines for Infectious Diseases Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global mRNA Vaccines for Infectious Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Type (2021-2032) Figure 12. Infectious Disease Image Figure 13. Cancer Image Figure 14. Global mRNA Vaccines for Infectious Diseases Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global mRNA Vaccines for Infectious Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Application (2021-2032) Figure 17. Global mRNA Vaccines for Infectious Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global mRNA Vaccines for Infectious Diseases Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America mRNA Vaccines for Infectious Diseases Sales Value (2021-2032) & (US$ Million) Figure 20. North America mRNA Vaccines for Infectious Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe mRNA Vaccines for Infectious Diseases Sales Value (2021-2032) & (US$ Million) Figure 22. Europe mRNA Vaccines for Infectious Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific mRNA Vaccines for Infectious Diseases Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific mRNA Vaccines for Infectious Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America mRNA Vaccines for Infectious Diseases Sales Value (2021-2032) & (US$ Million) Figure 26. South America mRNA Vaccines for Infectious Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa mRNA Vaccines for Infectious Diseases Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa mRNA Vaccines for Infectious Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Infectious Disease Vaccines
  • Cancer Vaccines
Applications
  • Infectious Disease
  • Cancer
Companies covered
  • Translate Bio
  • Tiba Biotechnology
  • Sangamo Therapeutics
  • Moderna Therapeutics
  • In-Cell-Art
  • Ethris
  • eTheRNA
  • CureVac
  • BioNTech
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global mRNA Vaccines for Infectious Diseases Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 mRNA Vaccines for Infectious Diseases Market Dynamics
  1. 2.1 mRNA Vaccines for Infectious Diseases Industry Trends
  2. 2.2 mRNA Vaccines for Infectious Diseases Industry Drivers
  3. 2.3 mRNA Vaccines for Infectious Diseases Industry Opportunities and Challenges
  4. 2.4 mRNA Vaccines for Infectious Diseases Industry Restraints
3 mRNA Vaccines for Infectious Diseases Market by Company
  1. 3.1 Global mRNA Vaccines for Infectious Diseases Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Vaccines for Infectious Diseases Company Ranking (2024-2026)
  4. 3.4 Global mRNA Vaccines for Infectious Diseases Company Manufacturing Base and Headquarters
  5. 3.5 Global mRNA Vaccines for Infectious Diseases Company Product Type and Application
  6. 3.6 Global mRNA Vaccines for Infectious Diseases Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global mRNA Vaccines for Infectious Diseases Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 mRNA Vaccines for Infectious Diseases Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 mRNA Vaccines for Infectious Diseases Market by Type
  1. 4.1 mRNA Vaccines for Infectious Diseases Type Introduction
  2. 4.1.1 Infectious Disease Vaccines
  3. 4.1.2 Cancer Vaccines
  4. 4.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Type
  5. 4.2.1 Global mRNA Vaccines for Infectious Diseases Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Type (2021-2032)
  7. 4.2.3 Global mRNA Vaccines for Infectious Diseases Sales Value Share by Type (2021-2032)
5 mRNA Vaccines for Infectious Diseases Market by Application
  1. 5.1 mRNA Vaccines for Infectious Diseases Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Application
  5. 5.2.1 Global mRNA Vaccines for Infectious Diseases Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Application (2021-2032)
  7. 5.2.3 Global mRNA Vaccines for Infectious Diseases Sales Value Share by Application (2021-2032)
6 mRNA Vaccines for Infectious Diseases Regional Value Analysis
  1. 6.1 Global mRNA Vaccines for Infectious Diseases Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Region (2021-2032)
  3. 6.2.1 Global mRNA Vaccines for Infectious Diseases Sales Value by Region: 2021-2026
  4. 6.2.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America mRNA Vaccines for Infectious Diseases Sales Value (2021-2032)
  7. 6.3.2 North America mRNA Vaccines for Infectious Diseases Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe mRNA Vaccines for Infectious Diseases Sales Value (2021-2032)
  10. 6.4.2 Europe mRNA Vaccines for Infectious Diseases Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific mRNA Vaccines for Infectious Diseases Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific mRNA Vaccines for Infectious Diseases Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America mRNA Vaccines for Infectious Diseases Sales Value (2021-2032)
  16. 6.6.2 South America mRNA Vaccines for Infectious Diseases Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa mRNA Vaccines for Infectious Diseases Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa mRNA Vaccines for Infectious Diseases Sales Value Share by Country, 2025 VS 2032
7 mRNA Vaccines for Infectious Diseases Country-level Value Analysis
  1. 7.1 Global mRNA Vaccines for Infectious Diseases Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Country (2021-2032)
  3. 7.2.1 Global mRNA Vaccines for Infectious Diseases Sales Value by Country (2021-2026)
  4. 7.2.2 Global mRNA Vaccines for Infectious Diseases Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt mRNA Vaccines for Infectious Diseases Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt mRNA Vaccines for Infectious Diseases Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt mRNA Vaccines for Infectious Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Translate Bio
  2. 8.1.1 Translate Bio Company Information
  3. 8.1.2 Translate Bio Business Overview
  4. 8.1.3 Translate Bio mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Translate Bio mRNA Vaccines for Infectious Diseases Product Portfolio
  6. 8.1.5 Translate Bio Recent Developments
  7. 8.2 Tiba Biotechnology
  8. 8.2.1 Tiba Biotechnology Company Information
  9. 8.2.2 Tiba Biotechnology Business Overview
  10. 8.2.3 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product Portfolio
  12. 8.2.5 Tiba Biotechnology Recent Developments
  13. 8.3 Sangamo Therapeutics
  14. 8.3.1 Sangamo Therapeutics Company Information
  15. 8.3.2 Sangamo Therapeutics Business Overview
  16. 8.3.3 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
  18. 8.3.5 Sangamo Therapeutics Recent Developments
  19. 8.4 Moderna Therapeutics
  20. 8.4.1 Moderna Therapeutics Company Information
  21. 8.4.2 Moderna Therapeutics Business Overview
  22. 8.4.3 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
  24. 8.4.5 Moderna Therapeutics Recent Developments
  25. 8.5 In-Cell-Art
  26. 8.5.1 In-Cell-Art Company Information
  27. 8.5.2 In-Cell-Art Business Overview
  28. 8.5.3 In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  29. 8.5.4 In-Cell-Art mRNA Vaccines for Infectious Diseases Product Portfolio
  30. 8.5.5 In-Cell-Art Recent Developments
  31. 8.6 Ethris
  32. 8.6.1 Ethris Company Information
  33. 8.6.2 Ethris Business Overview
  34. 8.6.3 Ethris mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ethris mRNA Vaccines for Infectious Diseases Product Portfolio
  36. 8.6.5 Ethris Recent Developments
  37. 8.7 eTheRNA
  38. 8.7.1 eTheRNA Company Information
  39. 8.7.2 eTheRNA Business Overview
  40. 8.7.3 eTheRNA mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  41. 8.7.4 eTheRNA mRNA Vaccines for Infectious Diseases Product Portfolio
  42. 8.7.5 eTheRNA Recent Developments
  43. 8.8 CureVac
  44. 8.8.1 CureVac Company Information
  45. 8.8.2 CureVac Business Overview
  46. 8.8.3 CureVac mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CureVac mRNA Vaccines for Infectious Diseases Product Portfolio
  48. 8.8.5 CureVac Recent Developments
  49. 8.9 BioNTech
  50. 8.9.1 BioNTech Company Information
  51. 8.9.2 BioNTech Business Overview
  52. 8.9.3 BioNTech mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioNTech mRNA Vaccines for Infectious Diseases Product Portfolio
  54. 8.9.5 BioNTech Recent Developments
  55. 8.10 Argos Therapeutics
  56. 8.10.1 Argos Therapeutics Company Information
  57. 8.10.2 Argos Therapeutics Business Overview
  58. 8.10.3 Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Argos Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
  60. 8.10.5 Argos Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst